Inovio, AstraZeneca deal
Inovio granted AstraZeneca’s MedImmune LLC unit exclusive, worldwide rights to develop and commercialize INO-3112. MedImmune plans to develop and commercialize INO-3112 in combination with undisclosed immunotherapy compounds in its pipeline. Additionally, the companies will develop up to two additional DNA-based cancer vaccine products not included in either company’s pipeline.
INO-3112 is a combination of VGX-3100, a DNA-based therapeutic vaccine targeting the E6 and E7 proteins of HPV 16 and 18, and INO-9012, an immune activator of IL-12. INO-3112 is in Phase I/IIa testing for HPV-associated head and neck cancer. Next year, MedImmune also intends to begin a Phase II trial of INO-3112 plus chemoradiotherapy to treat locally advanced cervical cancer. ...